The relationship between depression and regional cerebral blood flow in Parkinson's disease and the effect of selegiline treatment

Acta Neurologica Scandinavica

Volumn 124, Issue 1, 2011, Pages 28-39

  Imamura, K ^a   Okayasu, N ^a   Nagatsu, T ^b  

^a Okazaki City Hospital   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Depression; Parkinson's disease; Regional cerebral blood flow; Selegiline

Indexed keywords

IOFETAMINE I 123; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; BECK DEPRESSION INVENTORY; BRAIN BLOOD FLOW; BRAIN REGION; CASE CONTROL STUDY; COGNITION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CUNEUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; FEMALE; HIPPOCAMPUS; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; PARIETAL CORTEX; PARKINSON DISEASE; POSTERIOR CINGULATE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE; VISUAL CORTEX;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BLOOD CIRCULATION TIME; BRAIN; CEREBROVASCULAR CIRCULATION; DEPRESSIVE DISORDER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SELEGILINE; TREATMENT OUTCOME;

EID: 79958281616     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01443.x     Document Type: Article

References (29)

1. Cummings JL. Depression and Parkinson's disease: a review. Am J Psychiatry 1992;149:443-54.
2. Fibiger HC. The neurobiological substrates of depression in Parkinson's disease: a hypothesis. Can J Neurol Sci 1984;11:105-7.
3. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Regulation of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's Disease. Brain Res 1983;275:321-8.
4. Halliday GM, Li YW, Blumberg PC et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990;27:373-85.
5. Tom T, Cummings JL. Depression in Parkinson's disease. Pharmacological characteristics and treatment. Drugs Aging 1998;12:55-74.
6. Mayeux R, Stern Y, Cote L, Williams JBW. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984;34:642-6.
7. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996;57:449-54.
8. Przuntek H, Conrad B, Dichgans J et al. SELEDO: a 5-year long-term trial on the effect of selegiline in early parkinsonian patients treated with levodopa. Eur J Neurol 1999;6:141-50.
9. Palhagen S, Heinonen E, Hagglund J et al. Selegiline slows the progression of the symptoms of Parkinson's disease. Neurology 2006;66:1200-6.
10. Levin BE, Llabre MM, Weiner WJ. Parkinson's disease and depression: psychometric properties of the Beck Depression Inventory. J Neurol Neurosurg Psychiatry 1988;51:1401-4.
11. Schrag A, Barone P, Brown RG et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 2007;22:1077-92.
12. Takeuchi T, Sengoku T, Matsumura K. Usefulness of fully automated constant ROI analysis software for the brain: 3DSRT and FineSRT. Radiat Med 2006;24:538-44.
13. Reijnders JSDAM, Ehrt U, Weber WEJ, Aarsland D, Leentjents AFG. A systemic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008;23:183-9.
14. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988;45:497-501.
15. Chan-Palay V, Asan E. Alteration in catecholamine neurons of the locus ceruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989;287:373-92.
16. D'Amato RJ, Zweig RM, Whitehouse PJ et al. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann Neurol 1987;22:229-36.
17. Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry of depression. Brain Struct Funct 2008;213:93-118.
18. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997;9:471-81.
19. Ring HA, Bench CJ, Trimble MR, Brooks DJ, Frackowiak RS, Dolan RJ. Depression in Parkinson's disease: a single photon emission study. Br J Psychiatry 1994;165:333-9.
20. Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervations in the limbic system. Brain 2005;128:1314-22.
21. Fregni F, Ono CR, Santos CM et al. Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD. Neurology 2006;66:1629-37.
22. Hsu J-L, Jung T-P, Hsu C-Y et al. Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction. Eur J Nucl Med Mol Imaging 2007;34:1458-66.
23. Barone P, Scarzella L, Marconi R et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006;253:601-7.
24. Moryl E, Danysz W, Quack G. Potential antidepressive properties of amantadine, memantine and bifemelane. Phamacol Toxicol 1993;72:394-7.
25. Allain H, Pollak P, Neukirch HC. Members of the French Selegiline multicenter trial. Symptomatic effect of selegiline in de novo Parkinsonian patients. Mov Disord 1993;8(Suppl. 1):S36-40.
26. Silver JM, Yudofsky SC. Drug treatment of depression in Parkinson's disease. In: Huber SJ, Cummings JL, eds. Parkinson's disease: neurobehavioral aspects. New York: Oxford University Press, 1992;240-54.
27. Burke WJ, Peterson J, Rubin EH. Electroconvulsive therapy in the treatment of combined depression and Parkinson's disease. Psychosomatics 1988;29:341-6.
28. George MS, Wassermann EM, Post RM. Transcranial magnetic stimulation: a neuropsychiatric tool for the 21st century. J Neuropsychiatry Clin Neurosci 1996;8:373-82.
29. Ebadi M, Sharma S, Shavali S, El Refaey H. Neuroprotective actions of selegiline. J Neurosci Res 2002;67:285-9.